Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Comment by cpacon Feb 06, 2020 8:27am
117 Views
Post# 30650746

RE:Much like Tesla

RE:Much like Tesla Tesla went up ~400% this year and then pulled back 17% yesterday.  If you're telling me that Antibe will go up by multiples from here followed by a modest decline afterwards, I'll take it, lol.  Here's the thing about Tesla: The stock had a massive jump recently because the company DELIVERED earnings results above expectations with free cash flow generation to boot... this formed the basis of the short squeeze that ensured, but was, as I say based on a fundamental development.  Then, the company announced it expected delays to China shipments b/c of the coronoavirus, so the stock pulled back somewhat... still leaving it up 100s of percent for the year.  ANTIBE will soon deliver news of full enrollment and then the countdown starts until they deliver what are expected to be excellent phase IIb clinical results.  Then the fun really starts. :)

Magicbox, you went from informed contriubutor to goofy sourgrapes comments faster than a Formula One. :(

Cheers,
Cpac
Bullboard Posts